Clive Mean­well gives way to new CEO as ac­tivist in­vestor Alex Den­ner shakes up The Med­i­cines Com­pa­ny

Alex Den­ner has made his first pub­lic move at The Med­i­cines Com­pa­ny since con­sol­i­dat­ing pow­er on the board — and it’s a big one.

Clive Mean­well pass­ing the CEO role and his board seat to Mer­ck vet Mark Tim­ney, leav­ing a po­si­tion he’s oc­cu­pied for the bet­ter part of the com­pa­ny’s 22-year his­to­ry.

He’s not out en­tire­ly. In the new­ly-cre­at­ed role of chief in­no­va­tion of­fi­cer, he is tasked with sup­port­ing the on­go­ing de­vel­op­ment of in­clisir­an — the biotech’s ex­per­i­men­tal LDL-low­er­ing RNAi ther­a­py in-li­censed from Al­ny­lam.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER